trial · primary record
Acasunlimab
PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 191 |
| Primary completion | 2028-09-30 |
| Primary endpoint | Overall Survival (OS) |
| Registry ID | NCT06635824 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:48.140Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06635824
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.